Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature

Introduction: Apremilast, an oral phosphodiesterase-4 inhibitor, decreases the production of pro-inflammatory cytokines including tumour necrosis factor-α, interleukin-12/23, IL-12, IL-2, and interferon-γ; while upregulating the anti-inflammatory cytokine IL-10. Its pan-immunomodulatory nature has...

Full description

Bibliographic Details

Published in:	Nepal Journal of Dermatology, Venereology & Leprology
Main Author:	Saurabh Bhatia
Format:	Article
Language:	English
Published:	Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON) 2022-09-01
Subjects:	Alopecia Apremilast Dermatitis Dermatology Hidradenitis suppurativa Vitiligo
Online Access:	https://nepjol.info/index.php/NJDVL/article/view/45638